Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next Monday for another update.
PsyBio Therapeutics Announces Uplisting to OTCQB Venture Market
“Today’s news is an important milestone towards broadening our market presence across the United States as we engage with this significant shareholder audience,” said Evan Levine, CEO of PsyBio. Read more
Psytech To Merge With Wesana; Mycotopia Shareholders Will Benefit From The Transactions
PsyTech Inc, including the psychiatric therapeutic SaaS platform Tovana Solutions and psychiatric clinical network Tovana Clinics, to become a wholly-owned subsidiary of Wesana Health as part of a definitive agreement. Read more
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
Cybin announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy. Read more
MINDCURE Announces Filing of U.S. Provisional Patent for Ibogaine Compound
The company’s pharmaceutical-grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. Read more
Core One Labs Announces Details of Consolidation to Meet Nasdaq Listing Requirements
The Consolidation represents a significant step towards the listing of the Company on Nasdaq. The Company will continue to take steps to fulfill the other requirements set by Nasdaq for a successful listing application. Read more
Red Light Holland Merger Partner Creso Pharma Completes Acquisition of Halucenex
The acquisition of Halucenex followed considerable due diligence and marks Creso Pharma’s entry into the psychedelic-assisted psychotherapy sector. Read more
Optimi Health Joins First Psychedelic Exchange Traded Fund
The company is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (NEO: PSYK). Read more
PharmaDrug Reports Positive Preclinical Study Results of Cepharanthine to Treat Cancers
The company is pleased to announce interim positive results from its ongoing preclinical study evaluating the Company’s patented enteric-coated formulation of Cepharanthine (“PD-001”) in a broad panel of human cancers. Read more